Kornimate/medical-research-clean huggingface dataset:
utilizing advocates and supporters to increase lung cancer screening rates in eligible participants

Conditions: Breast Carcinoma; Lung Carcinoma

Summary: this clinical trial assesses the use of advocates and supporters of breast and lung cancer screening to increase lung cancer screening rates amongst eligible participants. imaging-based cancer screening is utilized with variable frequency. breast cancer screening with mammography has been widely accepted and is commonly used among eligible women. lung screening with computed tomography scans is poorly used, despite the potential to decrease deaths from lung cancer. there are many reasons lung screening isn't being used when compared to breast screening, such as smoking stigma and fear, along with a lack of awareness of lung screening. by conducting this trial, researchers want to assess the effectiveness of advocates and supporters of breast and lung screening, and to learn about the psychological barriers to cancer screening, identifying those that are unique to lung screening.

primary objectives: i. determine the number of patients undergoing breast screening who are eligible to participate in lung screening. ii. determine whether patients currently participating in cancer screening (breast or lung) are successful as "cancer screening advocates." iii. determine whether laypersons who are aware of screening (including those who accompany friends and family members to their screening appointments) are successful as "cancer screening advocates." iv. identify knowledge base and psychological barriers to screening through surveys of potential screening participants. outline: participants access an electronic patient portal with educational materials at baseline, 1- and 2-year follow-ups, and also interact with a patient navigator on study. patients also receive materials to share with their friends/family on benefits of breast and lung cancer screening on study. after completion of study intervention, participants are followed up yearly for up to 3 years.

Eligibility criteria:
inclusion criteria: * age: * breast screening \> 40 * lung screening 50-80 * male (m) or female (f) * current, former, or never smokers * close family or friend with smoking history (in or out of state) exclusion criteria: * age: * breast screening \< 40 * lung screening \ 80 * persons who had previously received a diagnosis of lung cancer, had hemoptysis, or had an unexplained weight loss of more than 6.8 kg (15 lb) in the preceding year will also be excluded * persons with an active cancer
a study of otezla® in patients with plaque psoriasis under routine conditions

Conditions: Psoriasis

Summary: the objective of this nis is the collection of data on the utilization of apremilast under routine conditions in germany. patients' quality-of-life and treatment satisfaction on treatment with apremilast in daily practice will be documented. moreover, physician's and patient's assessments of the effectiveness and safety of apremilast will be recorded. fpi was 3rd august 2015, lpo was 14th of june 2018. a total of 391 patients have been enrolled.

the objective of this nis (according to section 4(23) of the german medicinal products act) is the documentation of data on the effectiveness and tolerability of an apremilast treatment under routine clinical conditions in german patients with plaque psoriasis. this nis is intended to reflect the apremilast treatment of patients with plaque psoriasis who have received at least one prior conventional, systemic therapy or, if a contraindication is present, did not receive a systemic therapy so far, and who were diagnosed by their treating physicians to be eligible for an apremilast treatment. the treatment of apremilast will be documented for a period of approximately 52 weeks.

Eligibility criteria:
inclusion criteria: * the decision for a therapy with apremilast was made before enrolment and independent of this study. * patient ≥ 18 years of age * diagnosis of moderate to severe plaque psoriasis * inadequate response or intolerance to a previous systemic treatment, or contraindication for systemic therapies. * written informed consent by the patient for data recording, statistical analysis, filing and forwarding of the data exclusion criteria: * pregnancy * hypersensitivity to apremilast or any of the excipients of the film-coated tablet * other criteria according to the summary of product characteristics (smpc).

Keywords: plaque psoriasis apremilast otezla® lapis-pso observational cc-10004 non-interventional germany
pattern recognition prosthetic control

Conditions: Prosthesis User; Congenital Amputation of Upper Limb; Amputation; Traumatic, Limb

Summary: this study investigates whether simultaneous electromyographic (emg)-based pattern recognition control of an upper limb prostheses increases wear time among users. in contrast to conventional, seamless sequential pattern recognition style of control which only allows a single prosthetic hand or arm function at a time, simultaneous control allows for more than one at the same time. participants will wear their prosthesis as they would normally at home using each control style for an 8-week period with an intermittent 1-week washout period (17 weeks total). prosthetic usage will be monitored; including, how often participants wear their device and how many times they move each degree of freedom independently or simultaneously. the primary hypothesis is that prosthetic users will prefer simultaneous control over conventional control which will result in wearing their device more often. the secondary hypothesis is that simultaneous control will result in more efficient prosthesis control which will make it easier for participants to perform activities of daily living. the results of this study will help identify important factors related to prosthetic users' preferences while freely wearing their device within their own daily-life environment.


Eligibility criteria:
inclusion criteria: * subjects have an upper-limb difference (congenital or acquired) at the transradial (between the wrist and elbow), elbow disarticulation (at the elbow), transhumeral (between the elbow and shoulder), or shoulder disarticulation (at the shoulder) level. * subjects are suitable to be, or already are, a coapt pattern recognition user (coapt complete control gen2 device). * subjects are between the ages of 18 and 70. exclusion criteria: * subjects with significant cognitive deficits or visual impairment that would preclude them from giving informed consent or following instructions during the experiments, or the ability to obtain relevant user feedback discussion. * subjects who are non-english speaking. * subjects who are pregnant.

Keywords: pattern recognition home trial randomized cross-over trial prosthesis electromyography
assessment of carpal tunnel syndrome by shearwave elastography

Conditions: Carpal Tunnel Syndrome

Summary: this study is being done to test a new ultrasound method to detect possible stiffness problems within wrist(s). the purpose of this research is to the test the effectiveness of a new ultrasound method to check the nerve and surrounding tissue in both wrist of patient volunteers before and after treatment.

the ultrasound system is fda approved. the risks associated with this research study are not beyond the normal risk of conventional ultrasound and should not cause you any discomfort. ultrasound at the intensity levels and duration used in this study has not been shown to present risk to humans. the investigators will conduct the swe study on the set time point when the patient returns for follow-up after the therapy (surgical decompression or corticosteroid injection). a set of pictures will be taken of patients wrists by the fda approved ultrasound system. this system uses a special type of ultrasound for imaging your wrists. the ultrasound study will be repeated after 3 and 6 months after the treatments.

Eligibility criteria:
inclusion criteria: * male and female volunteers. * age ≥ 18 years old. * having unilateral symptom of wrist pain * scheduled for corticosteroid injection or surgery exclusion criteria: * individuals less than 18 years of age. * prior surgery. * people considered in "vulnerable" populations. * having bilateral symptoms

Keywords: shear wave elastography peripheral compression neuropathy neuropathy demyelination
utility of pharmacogenomic testing in patients with gastrointestinal disorders

Conditions: Gastrointestinal Diseases

Summary: researchers are trying to learn more about how individuals break down and process specific medications based on their genes. pharmacogenomics (pgx) is a new, specialized field within individualized medicine. pgx is the study of how genes may affect the body's response to, and interaction with, some prescription medications. genes carry information that determines things such as eye color and blood type. genes can also influence how individuals process and respond to medications. depending on genetic make-up, some medications may work faster or slower or produce fewer side effects.


Eligibility criteria:
inclusion criteria * rome iv criteria for functional nausea and vomiting disorders (chronic nausea vomiting syndrome, cyclic vomiting syndrome), abdominal bloating/distention, dyspepsia, irritable bowel syndrome, chronic abdominal pain, functional diarrhea, or chronic constipation. * on 1 or more medications identified in appendix 1 on a daily basis for at least six months. * symptoms of moderate or severe severity on either of these 2 instruments: for ibs-sss, use moderate (175-300) or severe (\> 300) ibs. for fd - score ≥ 3 for any symptom on nepean dyspepsia index. * no prior pharmacogenomics assessment. * willingness to adjust medications based upon results of pgx testing. * patients must understand and provide written informed consent and hipaa authorization prior to initiation of any study-specific procedures. * patients must have the ability to complete questionnaires by themselves or with assistance. exclusion criteria: * patients who decline to be evaluated by a mental health professional during their evaluation. * rumination syndrome, cannabinoid hyperemesis syndrome, patients with a significant gi disease process (e.g., intestinal pseudo-obstruction, severe gastroparesis, megacolon) which, in the opinion of the investigator, is likely irreversible. * patients who, in the opinion of the investigator, are likely to undergo another major therapeutic intervention during the next 6 months (e.g., surgery or pelvic floor retraining by biofeedback therapy). however, other changes (e.g., medications) will not preclude participation in the study. * patients with any of the following per history, and review of medical record prior to study entry: any psychotic disorders, bipolar disorders, or major cognitive disorders; any active substance use disorders, other than tobacco; currently active suicidal ideation; current treatment with electroconvulsive therapy (ect) or repetitive transcranial magnetic stimulation (rtms); discharge from a psychiatric inpatient hospital or intensive psychiatric outpatient program within 6 weeks prior to gi consultation. * patients who are unwilling or cannot, for any reason, adjust their medications.
corticosteroids for children with febrile urinary tract infections

Conditions: Acute Urinary Tract Infection; Urinary Tract Infection

Summary: in this study the investigators will determine whether corticosteroids given at the time of urinary tract infection help prevent permanent damage to the kidneys.

because host inflammatory response is the final and most important step in the formation of renal scars, the use of anti-inflammatory agents may be the best strategy to reduce renal scarring. in animal studies, the use of corticosteroids has been shown to be effective in preventing post-pyelonephritic scarring. we will conduct a randomized, double-blind, placebo-controlled trial to determine the efficacy of 3 days of daily adjuvant dexamethasone on the incidence of renal scarring 4 to 6 months after a first febrile urinary tract infection (uti). we hypothesize that the proportion of children with uti who develop renal scarring will be lower among children who are treated with both dexamethasone and antibiotics as compared with children treated with antibiotics alone.

Eligibility criteria:
inclusion criteria: * age: 2 months to 6 years * pyuria: ≥10 white blood cells per cubic millimeter (wbc/mm3) in an uncentrifuged specimen or ≥5 white blood cells per high power field (wbc/hpf) in a centrifuged specimen or ≥1+ leukocyte esterase (le) on dipstick * fever: documented temperature of at least 101 °f or 38.3°c, measured anywhere on the body either at home or at doctor's office within 24 hours of diagnosis exclusion criteria: * other concurrent systemic bacterial infection(s) such as meningitis or pneumonia; * planned admission to intensive care unit; * known bacteremia; * previous protocol defined uti; * known major urinary tract anomalies (severe hydronephrosis, ureterocele, urethral valve, solitary or profoundly small kidney, multicystic dysplastic kidney, neurogenic bladder, pelvic or fused kidney); * congenital/acquired immunodeficiency; * bag urine collection * chronic diseases that could potentially interfere with response to therapy, such as chronic gastrointestinal conditions (i.e. malabsorption, inflammatory bowel disease), liver/kidney failure; * allergy to dexamethasone * antibiotic use within 7 days of enrollment (except if given in the last 48 hours) * systemic use of corticosteroids or other immunomodulating agents within 14 days of enrollment * history of kawasaki disease * sickle cell disease (not trait)

Keywords: renal scarring dexamethasone child corticosteroids pediatric urinary tract infection escherichia coli urinary tract infection
the development and effectiveness of museum-based experiences for individuals with chronic pain

Conditions: Chronic Pain

Summary: aim 1: to conduct a formative evaluation of museum-based programming to address loneliness and social isolation. aim 2: to develop a consensus-derived model museum-based program (mmbp) to address loneliness among individuals with chronic pain. aim 3: to evaluate the feasibility of museum experiences to reduce loneliness and pain among isolated individuals with chronic pain. due to safety concerns related to the covid pandemic in-person museum programming could not continue and virtual versions of the interventions were created. we will publish results on both the in-person and virtual versions of the intervention as well as a pooled analysis.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * english speaking * chronic pain (6 months or longer) * moderate pain or greater (4/10 or greater on a numerical rating scale, range of 0 (no pain) - 10 (worst pain imaginable), in response to the question "over the past week what was your average pain intensity?") * moderately lonely or greater (score of 4 or greater on 3 item loneliness scale, range of 3 - 9) exclusion criteria: * participated in an art rx tour * participated in an artful meditation program * dementia or alzheimer's disease
assessment of musculoskeletal pain and psychosocial status of athletes

Conditions: Pain

Summary: the sporty performance exhibited by an athlete faces physiological, biomechanical and psychological activity of the athlete. it depends on both the psychological state and the elevation of the musculoskeletal system to a certain level so that the athlete can perform optimally and excellently. for this reason, we aimed to evaluate the musculoskeletal system pain of amateur and professional athletes in different disciplines and the psychosocial states such as sports confidence, depression and quality of life.

this study consists of 160 sportsmen who are participating in sports by doing sports in soccer, basketball, volleyball, athletics, table tennis, field tennis, kickboxing and archery branches between the ages of 15 and 36. the expanded scandinavian muscle skeleton questionnaire (nmq) and visible analogue scale (vas) will be used to identify and assess the symptoms of musculoskeletal discomfort as 'pain'. the participant will be evaluated with the algometer for identifying their pain threshold, the sporty trust will be questioned with the sporty trust continuous inventory, and the quality of life will be assessed with the world health organization quality of life scale short form and depression will be evaluated with beck depression inventory.

Eligibility criteria:
inclusion criteria: * the athletes and their coaches must be voluntary and willing. * during the evaluation, the athletes must give careful and relevant answers to the measuring instruments. * they have to actively run the sport they belong to. * the dominant upper extremity should be the right side. exclusion criteria: * having undergone a surgical operation due to sports injuries in the last 3 weeks * the athletes do not want to answer the surveying instruments

Keywords: musculoskeletal system pain athlete psychosocial problems algometer
identification of pre-surgical phenotypic indicators predictive of quality of life trajectories in obese patients following bariatric surgery

Conditions: Obesity, Morbid; Obesity and Overweight; Bariatric Surgery; Bariatric Surgery Patients; Bariatric Surgery Patient; Bariatric Surgery (Sleeve Gastrectomy ); Bypass, Gastric

Summary: this study aims to identify pre-operative phenotypic determinants predictive of quality of life trajectories in post-bariatric surgery patients. in addition, this study will have as a secondary objective the highlighting of a potential link between post-surgery quality of life trajectories and those of anxiety/depression scores, eating behaviors and body mass indices. this study will be conducted during the usual care of patients undergoing the gerom73 program, lasting a total of 30 months. the gerom73 program includes care for the six months preceding bariatric surgery and the 24 months following surgery. this program supports patients throughout their bariatric care.. throughout the gerom73 program, patients will complete questionnaires on anxiety, depression, eating disorders, impact of weight on quality of life. patients' weight, body mass index and body schema will also be measured throughout the gerom program.


Eligibility criteria:
inclusion criteria: * patient \> 18years old * integrated into the gerom73 surgical program and starting the intra-hospital program exclusion criteria: * patients in a state of psychiatric decompensation * patients with cognitive disorders * patients with difficulties understanding the french language, spoken or written * pregnant, parturient, or breastfeeding women

Keywords: gerom73 phenobeqol73
the abc trial does all-blood cardioplegia prevent blood transfusion in cardiac surgery? a single centre pilot study

Conditions: Coronary Artery Disease; Valvular Heart Disease

Summary: this study is a single centre pilot for a randomized trial comparing all-blood cardioplegia to more dilute 4:1 blood cardioplegia during cardiac surgery. the hypothesis is that all-blood cardioplegia will be associated with less blood transfusion and better cardiac function.

this is a single centre randomized, double blind, 2 arm, parallel group pilot study comparing all-blood cardioplegia to 4:1 blood cardioplegia in patients undergoing cardiac surgery. this pilot study will support the design of a larger multicentre trial. subjects undergoing cardiac surgery will be randomized to receive either standard of care (4:1) or all-blood cardioplegia for myocardial protection. neither of these cardioplegia approaches would be considered investigational. each is in use at numerous cardiac surgical centres around the world. the cardioplegia will be delivered using the quest medical mps system which is a health canada approved device. clinical endpoints will be evalauted (rate of blood transtransfusion, icu stay, etc...). in a subset of subjects who meet specific criteria, ventricular function will be evaluated in the operating room using the cd leycom inca conductance catheter system.

Eligibility criteria:
inclusion criteria: * patients (male and female) undergoing isolated coronary artery bypass grafting, * isolated aortic or mitral repair or replacement, and * combined aortic or mitral valve repair or replacement and * coronary bypass grafting exclusion criteria: * reoperation, * endocarditis, * dialysis dependant renal failure, * pre-operative ecmo or lvad support, * contraindication to blood transfusion (ie. jehovah's witness), and * use of irreversible anti-platelet (other than asa) and anticoagulant agents within 48h (ie. plavix, dabigitran, gpiib/iiia inhibitors, argatroban).

Keywords: cardioplegia blood transfusion cardiac function myocardial edema coronary artery disease valve disease
effectiveness of mindfulness after a stroke

Conditions: Stroke; Caregiver Burnout

Summary: mindfulness is promising for individuals with neurological disorders and caregivers to improve psychological well-being. this study aims to determine the extent to which a 3-week online mindfulness intervention will improve quality of life and psychological well-being for chronic stroke survivors and their caregivers, compared to a waitlist control.

background: the incidence of depression and anxiety is much higher in stroke survivors and their caregivers compared to age-matched peers. previous work suggests that mindfulness delivered in an online format is promising for both individuals with neurological disorders and caregivers to improve quality of life and psychological well-being. aim: this project aims to determine the extent to which a 3-week online mindfulness intervention will improve quality of life and psychological well-being for chronic stroke survivors and their caregivers, compared to a waitlist control. the primary hypothesis is that participants in the mindfulness group will demonstrate greater improvement in quality of life and psychological well-being post-intervention compared to waitlist control participants. the secondary hypothesis is that these improvements will persist for at least 1-month post-intervention. methods: this project uses a pragmatic, randomized, waitlist-control trial design with blinded outcome assessment. participants (stroke survivors and caregivers) are assigned to a 3-week online mindfulness intervention, or a 2-month delayed waitlist. a battery of self-reported outcome measures and clinical tests are administered pre-intervention, post-intervention and at 1-month follow-up. participants in the waitlist control group are also assessed at enrollment. a sample of 44 stroke survivors and 44 caregivers is targeted. changes will be measured using a repeated analysis of variance. conclusion: the study constitutes the initial step to understand the role of mindfulness exercises delivered remotely and the potential benefit of the intervention for stroke survivors across a wide range of disability level and their caregivers.

Eligibility criteria:
inclusion criteria: * stroke survivor or caregiver of someone who have had a stroke * fluent in english * have access to internet using a computer, a tablet and/or a smart phone. exclusion criteria: * severe language impairments * participation in regular meditation or a mindfulness program in past 3 months

Keywords: mindfulness rehabilitation caregiver attention to variability